Our strategy and business model
Focus on unmet medical needs resulting from specific genetic mutations, drug resistance, or compensatory mechanisms
Build a portfolio of internally discovered and selectively acquired programs structured into asset-based subsidiaries
Fast track promising assets from discovery to clinical proof of concept
Advance programs into pivotal studies and commercialization through creative partnerships
Leverage proven and synergistic capabilities of Jubilant Pharmova's world-class research with in-house development expertise